Does the media refer more to BCYC or YARW?

In the previous week, Yarrow Bioscience had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 2 mentions for Yarrow Bioscience and 1 mentions for Bicycle Therapeutics. Yarrow Bioscience's average media sentiment score of 0.97 beat Bicycle Therapeutics' score of 0.34 indicating that Yarrow Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Yarrow Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor YARW or GALT?

In the previous week, Yarrow Bioscience had 1 more articles in the media than Galectin Therapeutics. MarketBeat recorded 2 mentions for Yarrow Bioscience and 1 mentions for Galectin Therapeutics. Yarrow Bioscience's average media sentiment score of 0.97 beat Galectin Therapeutics' score of 0.67 indicating that Yarrow Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Yarrow Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor YARW or CAMP?

In the previous week, CAMP4 Therapeutics had 7 more articles in the media than Yarrow Bioscience. MarketBeat recorded 9 mentions for CAMP4 Therapeutics and 2 mentions for Yarrow Bioscience. Yarrow Bioscience's average media sentiment score of 0.97 beat CAMP4 Therapeutics' score of -0.12 indicating that Yarrow Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Yarrow Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CAMP4 Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor YARW or IRON?

In the previous week, Yarrow Bioscience and Yarrow Bioscience both had 2 articles in the media. Yarrow Bioscience's average media sentiment score of 0.97 beat Disc Medicine's score of 0.41 indicating that Yarrow Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Yarrow Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Disc Medicine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor YARW or IVVD?

In the previous week, Invivyd had 10 more articles in the media than Yarrow Bioscience. MarketBeat recorded 12 mentions for Invivyd and 2 mentions for Yarrow Bioscience. Invivyd's average media sentiment score of 1.10 beat Yarrow Bioscience's score of 0.97 indicating that Invivyd is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Yarrow Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Invivyd 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Yarrow Bioscience (YARW) Competitors

$22.27 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$22.36 +0.09 (+0.38%)

As of 04:51 AM Eastern

Compare

YARW vs. BCYC, GALT, CAMP, IRON, and IVVD

Should you buy Yarrow Bioscience stock or one of its competitors? Yarrow Bioscience's main competitors and comparable companies include Bicycle Therapeutics (BCYC), Galectin Therapeutics (GALT), CAMP4 Therapeutics (CAMP), Disc Medicine (IRON), and Invivyd (IVVD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Yarrow Bioscience compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are owned by institutional investors. 22.0% of Bicycle Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Yarrow Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Yarrow Bioscience has lower revenue, but higher earnings than Bicycle Therapeutics. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.25	-$218.96M	-$2.73	N/A
Yarrow Bioscience	$570K	104.32	-$26.48M	-$14.64	N/A

In the previous week, Yarrow Bioscience had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 2 mentions for Yarrow Bioscience and 1 mentions for Bicycle Therapeutics. Yarrow Bioscience's average media sentiment score of 0.97 beat Bicycle Therapeutics' score of 0.34 indicating that Yarrow Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Yarrow Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bicycle Therapeutics has a net margin of -311.11% compared to Yarrow Bioscience's net margin of -4,726.21%. Bicycle Therapeutics' return on equity of -33.22% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%

Bicycle Therapeutics presently has a consensus price target of $13.86, indicating a potential upside of 309.97%. Yarrow Bioscience has a consensus price target of $58.00, indicating a potential upside of 160.44%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Bicycle Therapeutics is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Bicycle Therapeutics has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, Yarrow Bioscience has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market.

Summary

Bicycle Therapeutics beats Yarrow Bioscience on 11 of the 16 factors compared between the two stocks.

How does Yarrow Bioscience compare to Galectin Therapeutics?

Yarrow Bioscience (NASDAQ:YARW) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

Yarrow Bioscience has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

In the previous week, Yarrow Bioscience had 1 more articles in the media than Galectin Therapeutics. MarketBeat recorded 2 mentions for Yarrow Bioscience and 1 mentions for Galectin Therapeutics. Yarrow Bioscience's average media sentiment score of 0.97 beat Galectin Therapeutics' score of 0.67 indicating that Yarrow Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Yarrow Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galectin Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Galectin Therapeutics has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Galectin Therapeutics' return on equity of 0.00% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%
Galectin Therapeutics	N/A	N/A	-176.83%

83.8% of Yarrow Bioscience shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 3.0% of Yarrow Bioscience shares are held by company insiders. Comparatively, 52.6% of Galectin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Yarrow Bioscience has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570K	104.32	-$26.48M	-$14.64	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A

Yarrow Bioscience presently has a consensus target price of $58.00, indicating a potential upside of 160.44%. Galectin Therapeutics has a consensus target price of $11.00, indicating a potential upside of 182.05%. Given Galectin Therapeutics' higher probable upside, analysts clearly believe Galectin Therapeutics is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Yarrow Bioscience beats Galectin Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Yarrow Bioscience compare to CAMP4 Therapeutics?

Yarrow Bioscience (NASDAQ:YARW) and CAMP4 Therapeutics (NASDAQ:CAMP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Yarrow Bioscience presently has a consensus price target of $58.00, suggesting a potential upside of 160.44%. CAMP4 Therapeutics has a consensus price target of $10.17, suggesting a potential upside of 154.17%. Given Yarrow Bioscience's higher probable upside, research analysts plainly believe Yarrow Bioscience is more favorable than CAMP4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

83.8% of Yarrow Bioscience shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by insiders. Comparatively, 21.7% of CAMP4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Yarrow Bioscience has higher earnings, but lower revenue than CAMP4 Therapeutics. CAMP4 Therapeutics is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570K	104.32	-$26.48M	-$14.64	N/A
CAMP4 Therapeutics	$3.50M	71.71	-$80.40M	-$2.32	N/A

In the previous week, CAMP4 Therapeutics had 7 more articles in the media than Yarrow Bioscience. MarketBeat recorded 9 mentions for CAMP4 Therapeutics and 2 mentions for Yarrow Bioscience. Yarrow Bioscience's average media sentiment score of 0.97 beat CAMP4 Therapeutics' score of -0.12 indicating that Yarrow Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Yarrow Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CAMP4 Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Yarrow Bioscience has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market. Comparatively, CAMP4 Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

CAMP4 Therapeutics has a net margin of -2,543.74% compared to Yarrow Bioscience's net margin of -4,726.21%. Yarrow Bioscience's return on equity of -84.40% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%

Summary

Yarrow Bioscience beats CAMP4 Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Yarrow Bioscience compare to Disc Medicine?

Yarrow Bioscience (NASDAQ:YARW) and Disc Medicine (NASDAQ:IRON) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

83.8% of Yarrow Bioscience shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 3.0% of Yarrow Bioscience shares are held by company insiders. Comparatively, 3.8% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Yarrow Bioscience currently has a consensus target price of $58.00, suggesting a potential upside of 160.44%. Disc Medicine has a consensus target price of $110.18, suggesting a potential upside of 70.80%. Given Yarrow Bioscience's higher probable upside, equities analysts plainly believe Yarrow Bioscience is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Yarrow Bioscience has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570K	104.32	-$26.48M	-$14.64	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A

Disc Medicine has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Disc Medicine's return on equity of -37.17% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%
Disc Medicine	N/A	-37.17%	-33.65%

Yarrow Bioscience has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

In the previous week, Yarrow Bioscience and Yarrow Bioscience both had 2 articles in the media. Yarrow Bioscience's average media sentiment score of 0.97 beat Disc Medicine's score of 0.41 indicating that Yarrow Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Yarrow Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Disc Medicine	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Yarrow Bioscience and Disc Medicine tied by winning 7 of the 14 factors compared between the two stocks.

How does Yarrow Bioscience compare to Invivyd?

Yarrow Bioscience (NASDAQ:YARW) and Invivyd (NASDAQ:IVVD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

In the previous week, Invivyd had 10 more articles in the media than Yarrow Bioscience. MarketBeat recorded 12 mentions for Invivyd and 2 mentions for Yarrow Bioscience. Invivyd's average media sentiment score of 1.10 beat Yarrow Bioscience's score of 0.97 indicating that Invivyd is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Yarrow Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Invivyd	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Yarrow Bioscience presently has a consensus target price of $58.00, suggesting a potential upside of 160.44%. Invivyd has a consensus target price of $8.00, suggesting a potential upside of 873.12%. Given Invivyd's higher possible upside, analysts clearly believe Invivyd is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

83.8% of Yarrow Bioscience shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 3.0% of Yarrow Bioscience shares are held by company insiders. Comparatively, 12.3% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Yarrow Bioscience has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market. Comparatively, Invivyd has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Invivyd has a net margin of -183.90% compared to Yarrow Bioscience's net margin of -4,726.21%. Invivyd's return on equity of -59.73% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%
Invivyd	-183.90%	-59.73%	-48.97%

Yarrow Bioscience has higher earnings, but lower revenue than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570K	104.32	-$26.48M	-$14.64	N/A
Invivyd	$53.43M	4.54	-$52.49M	-$0.33	N/A

Summary

Invivyd beats Yarrow Bioscience on 10 of the 15 factors compared between the two stocks.

Get Yarrow Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YARW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

YARW vs. The Competition

Export

Metric	Yarrow Bioscience	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$59.46M	$3.85B	$7.14B	$13.26B
Dividend Yield	N/A	3.65%	2.53%	17.33%
P/E Ratio	-1.52	13.06	275.01	26.04
Price / Sales	104.32	1,292.14	609.36	91.95
Price / Cash	N/A	39.04	27.22	34.69
Price / Book	0.53	16.69	10.99	6.34
Net Income	-$26.48M	-$23.20M	$3.50B	$381.61M
7 Day Performance	-7.21%	-2.86%	-1.98%	-0.73%
1 Month Performance	-26.28%	-10.82%	-6.31%	-4.68%
1 Year Performance	N/A	18.93%	7.99%	1.58%

Yarrow Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
YARW Yarrow Bioscience	2.8641 of 5 stars	$22.27 flat	$58.00 +160.4%	N/A	$59.46M	$570K	N/A	30	Gap Up
BCYC Bicycle Therapeutics	2.5679 of 5 stars	$3.68 +0.8%	$13.86 +276.6%	-59.6%	$257.57M	$61.21M	N/A	288	Gap Up
GALT Galectin Therapeutics	1.8097 of 5 stars	$3.85 -1.5%	$11.00 +185.7%	-9.9%	$253.56M	N/A	N/A	9
CAMP CAMP4 Therapeutics	3.7495 of 5 stars	$3.95 +2.6%	$9.71 +145.9%	+33.3%	$247.80M	$3.50M	N/A	644	Analyst Downgrade Gap Down
IRON Disc Medicine	2.7275 of 5 stars	$64.61 -0.5%	$110.18 +70.5%	-4.8%	$247.47M	N/A	N/A	165

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:YARW) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Yarrow Bioscience (YARW) Competitors

YARW vs. BCYC, GALT, CAMP, IRON, and IVVD

How does Yarrow Bioscience compare to Bicycle Therapeutics?

Summary

How does Yarrow Bioscience compare to Galectin Therapeutics?

Summary

How does Yarrow Bioscience compare to CAMP4 Therapeutics?

Summary

How does Yarrow Bioscience compare to Disc Medicine?

Summary

How does Yarrow Bioscience compare to Invivyd?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

YARW vs. The Competition

Yarrow Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Yarrow Bioscience (YARW) Competitors

YARW vs. BCYC, GALT, CAMP, IRON, and IVVD

How does Yarrow Bioscience compare to Bicycle Therapeutics?

Do insiders & institutionals hold more shares of BCYC or YARW?

Which has preferable earnings & valuation, BCYC or YARW?

Does the media refer more to BCYC or YARW?

Is BCYC or YARW more profitable?

Do analysts prefer BCYC or YARW?

Which has more risk and volatility, BCYC or YARW?

Summary

How does Yarrow Bioscience compare to Galectin Therapeutics?

Which has more risk & volatility, YARW or GALT?

Does the media favor YARW or GALT?

Is YARW or GALT more profitable?

Do insiders & institutionals believe in YARW or GALT?

Which has preferable earnings and valuation, YARW or GALT?

Do analysts recommend YARW or GALT?

Summary

How does Yarrow Bioscience compare to CAMP4 Therapeutics?

Do analysts prefer YARW or CAMP?

Do insiders & institutionals have more ownership in YARW or CAMP?

Which has higher earnings and valuation, YARW or CAMP?

Does the media favor YARW or CAMP?

Which has more volatility and risk, YARW or CAMP?

Is YARW or CAMP more profitable?

Summary

How does Yarrow Bioscience compare to Disc Medicine?

Do institutionals and insiders have more ownership in YARW or IRON?

Do analysts recommend YARW or IRON?

Which has stronger valuation and earnings, YARW or IRON?

Is YARW or IRON more profitable?

Which has more volatility & risk, YARW or IRON?

Does the media favor YARW or IRON?

Summary

How does Yarrow Bioscience compare to Invivyd?

Does the media favor YARW or IVVD?

Do analysts rate YARW or IVVD?

Do insiders & institutionals have more ownership in YARW or IVVD?

Which has more risk and volatility, YARW or IVVD?

Is YARW or IVVD more profitable?

Which has higher valuation and earnings, YARW or IVVD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

YARW vs. The Competition

Yarrow Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools